Stay updated on Volitinib for Primary CNS Tumors Clinical Trial
Sign up to get notified when there's something new on the Volitinib for Primary CNS Tumors Clinical Trial page.

Latest updates to the Volitinib for Primary CNS Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThis change removes links and files for critical study documents from the record, including consent forms and the protocol; the study page will have fewer references to its foundational materials and procedures.SummaryDifference23%

- Check15 days agoChange DetectedThe page now shows Revision: v3.7.0, replacing the previous v3.6.6, signaling a routine platform update rather than a modification to the study details.SummaryDifference0.0%

- Check29 days agoChange DetectedRevision: v3.6.6 replaces v3.6.5 on the page, indicating a new build of the site's framework or styling. This update appears to be a backend/software change with no visible changes to the study information.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page revision identifier was updated from v3.6.4 to v3.6.5, indicating a new version of the page. This appears to be a maintenance/metadata update rather than a change to the study content.SummaryDifference0.0%

- Check58 days agoChange DetectedA new Phase I Savolitinib study title is added, expanding the scope to MET-activated CNS tumors and listing related drug names (Orpathys, HMPL504, AZD-6094). Minor eligibility wording changes (serum creatinine) and procedural updates (e.g., Sample Collection) are also reflected.SummaryDifference0.6%

- Check65 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, indicating a new build. The previous revision tag was removed.SummaryDifference0.0%

Stay in the know with updates to Volitinib for Primary CNS Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Volitinib for Primary CNS Tumors Clinical Trial page.